مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

144
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

90
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

Pramipexole Versus Selegiline in Patients with Parkinson’ s Disease: An Effectiveness and Safety (EAS) Analysis

Pages

  0-0

Abstract

 Background: Levodopa treatment is the gold standard in Parkinson’ s disease but has the risk of Dyskinesias. Selegiline delays the introduction of Levodopa and Pramipexole is used as a symptomatic treatment in Parkinson’ s disease. Objectives: This study aimed to compare the effectiveness of Pramipexole with Selegiline in Parkinson’ s disease patients. Methods: Data regarding Motor and cognitive impairments and plasma Phospholipids of 500 Chinese patients with confirmed Parkinson’ s disease from medical records of 1 January 2015 to 1 June 2016 were retrospectively evaluated. Patients received either Pramipexole (PP cohort, n = 250) or Selegiline (SG cohort, n = 250). Also, data regarding hospitalization, adverse effects, and expenditure were collected and analyzed from records of the follow-up period. Results: After 3-years of treatments, Selegiline and Pramipexole both improved Motor and cognitive impairments and decreased plasma phospholipid levels (P < 0. 05 for all). The intensity of improvement in Motor and cognitive impairments and a decrease in the level of plasma Phospholipids for Pramipexole was higher than those of Selegiline (P < 0. 05 for all). Pramipexole caused muscle weakness (P = 0. 015) and peripheral edema (P = 0. 0004). While, Selegiline caused cardiovascular disease (P = 0. 008). Higher numbers of patients in the SG cohort were hospitalized during 3-years of treatment than those in PP cohort (11 vs. 1, P = 0. 009). Selegiline treatment is more expensive than Pramipexole (4, 457 345 ¥ vs. 3, 649 301 ¥ /patient/year, P < 0. 0001). Conclusions: Pramipexole treatment may have better improvement in Motor and cognitive impairments than Selegiline with neuroprotective action and manageable side effects (Level of Evidence: III).

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Tao, Zhonghai, Chen, Jiechun, Xiao, Lijie, & Liu, Chunfeng. (2019). Pramipexole Versus Selegiline in Patients with Parkinson’ s Disease: An Effectiveness and Safety (EAS) Analysis. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), 21(9), 0-0. SID. https://sid.ir/paper/749735/en

    Vancouver: Copy

    Tao Zhonghai, Chen Jiechun, Xiao Lijie, Liu Chunfeng. Pramipexole Versus Selegiline in Patients with Parkinson’ s Disease: An Effectiveness and Safety (EAS) Analysis. IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)[Internet]. 2019;21(9):0-0. Available from: https://sid.ir/paper/749735/en

    IEEE: Copy

    Zhonghai Tao, Jiechun Chen, Lijie Xiao, and Chunfeng Liu, “Pramipexole Versus Selegiline in Patients with Parkinson’ s Disease: An Effectiveness and Safety (EAS) Analysis,” IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ), vol. 21, no. 9, pp. 0–0, 2019, [Online]. Available: https://sid.ir/paper/749735/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button